CHCHD10

Across TCGA pan-cancer cohorts, CHCHD10 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CHCHD10 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CHCHD10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHCHD10 expression acts as an unfavorable survival marker.

BLCA and KIRC are the cancer types where CHCHD10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.078	0.616	<.001	24	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CHCHD10–BLCA (DFS)

Open the BLCA breakdown →